悦康药业(688658.SH)：子公司注射用YKYY031获得国家药品监督管理局临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) has received approval from the National Medical Products Administration (NMPA) for its clinical trial of the injectable YKYY031, a generic mRNA tumor vaccine intended for the treatment of advanced solid tumors [1] Group 1 - The clinical trial approval is granted to Yuyuan Pharmaceutical's wholly-owned subsidiary, Beijing Yuyuan Kete Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. [1] - YKYY031 is designed to treat advanced solid tumors and utilizes a novel cationic lipid YK-009-based lipid nanoparticle (LNP) delivery system, which is characterized by high delivery efficiency and good safety [1]